AstraZeneca Plans 20 New Medicines By 2030

AstraZeneca Pharma India is sharpening its focus on growth, access, and innovation as it looks ahead to FY26. The company, led by Praveen Rao Akkinepally, Country President and MD, reported 36% growth in the latest quarter and plans to sustain double-digit expansion. Priorities include, expanding oncology access through precision medicines and partnerships, and investing ₹550 crore locally to boost research, AI efforts, and jobs. With over 60 ongoing clinical trials in India, AstraZeneca aims to strengthen local R&D and diagnostics, positioning the country as a hub for innovation while ensuring patients benefit from the latest treatments.